Literature DB >> 18812163

AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol.

Elham Zarrinpashneh1, Christophe Beauloye, Audrey Ginion, Anne-Catherine Pouleur, Xavier Havaux, Louis Hue, Benoit Viollet, Jean-Louis Vanoverschelde, Luc Bertrand.   

Abstract

As AMP-activated protein kinase (AMPK) controls protein translation, an anti-hypertrophic effect of AMPK has been suggested. However, there is no genetic evidence to confirm this hypothesis. We investigated the contribution of AMPKalpha2 in the control of cardiac hypertrophy by using AMPKalpha2-/- mice submitted to isoproterenol. The isoproterenol-induced cardiac hypertrophy, measured by left ventricular mass and histological examination, was significantly higher in AMPKalpha2-/- than in WT animals. Moreover, the intensification of cardiac hypertrophy found in AMPKalpha2-/- mice can be linked to the abnormal basal overstimulation of the p70 ribosomal S6 protein kinase, an enzyme known to regulate protein translation and cell growth. In conclusion, this work shows that AMPKalpha2 plays a role of brake for the development of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812163     DOI: 10.1016/j.bbrc.2008.09.057

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Resveratrol prevents pathological but not physiological cardiac hypertrophy.

Authors:  Vernon W Dolinsky; Carrie-Lynn M Soltys; Kyle J Rogan; Anita Y M Chan; Jeevan Nagendran; Shaohua Wang; Jason R B Dyck
Journal:  J Mol Med (Berl)       Date:  2014-11-15       Impact factor: 4.599

2.  CHIP protects against cardiac pressure overload through regulation of AMPK.

Authors:  Jonathan C Schisler; Carrie E Rubel; Chunlian Zhang; Pamela Lockyer; Douglas M Cyr; Cam Patterson
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

3.  Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation.

Authors:  Yong-nan Fu; Han Xiao; Xiao-wei Ma; Sheng-yang Jiang; Ming Xu; You-yi Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-05-09       Impact factor: 6.150

4.  AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism.

Authors:  Miranda M Sung; Beshay N Zordoky; Adam L Bujak; James S V Lally; David Fung; Martin E Young; Sandrine Horman; Edward J Miller; Peter E Light; Bruce E Kemp; Gregory R Steinberg; Jason R B Dyck
Journal:  Cardiovasc Res       Date:  2015-05-28       Impact factor: 10.787

Review 5.  AMP-activated protein kinase in the control of cardiac metabolism and remodeling.

Authors:  Sandrine Horman; Christophe Beauloye; Jean-Louis Vanoverschelde; Luc Bertrand
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 6.  Regulation of NAD(P)H oxidases by AMPK in cardiovascular systems.

Authors:  Ping Song; Ming-Hui Zou
Journal:  Free Radic Biol Med       Date:  2012-02-04       Impact factor: 7.376

Review 7.  Molecular basis of physiological heart growth: fundamental concepts and new players.

Authors:  Marjorie Maillet; Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2013-01       Impact factor: 94.444

Review 8.  LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.

Authors:  R J Shaw
Journal:  Acta Physiol (Oxf)       Date:  2009-02-19       Impact factor: 6.311

9.  Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathway.

Authors:  Zhen-Guo Ma; Jia Dai; Wen-Bin Zhang; Yuan Yuan; Hai-Han Liao; Ning Zhang; Zhou-Yan Bian; Qi-Zhu Tang
Journal:  Br J Pharmacol       Date:  2016-03-14       Impact factor: 8.739

Review 10.  AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System.

Authors:  Ian P Salt; D Grahame Hardie
Journal:  Circ Res       Date:  2017-05-26       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.